EGFR inhibitors
Some targeted therapy medicines aim for a protein on cells called the epidermal growth factor receptor (EGFR). Sometimes NSCLC cells have too much EGFR. This makes them grow faster. Blocking EGFR stops these signals and can keep the cancer cell from growing.
These are some of the medicines that can be used if your lung cancer cells have certain EGFR gene changes (mutations):
- Erlotinib
- Afatinib
- Gefitinib
- Osimertinib
- Dacomitinib
All of these medicines are taken as pills.
Necitumumab is an EGFR inhibitor that can be used in people with the squamous cell sub-type of NSCLC. This medicine is given by I.V. (intravenous) infusion into a vein.
Angiogenesis inhibitors
Some targeted therapy medicines target new blood vessel growth. This process is called angiogenesis. Tumors need new blood vessels to grow. So keeping the tumors from making new blood vessels can help keep them from growing. These medicines are often used along with chemotherapy for more advanced NSCLC:
These medicines are given by I.V. They go right into your blood through a vein.
ALK inhibitors
A small number of NSCLCs have changes in the ALK gene. This change makes an abnormal ALK protein that causes the cancer cells to grow and spread. Medicines that target the abnormal ALK protein can often help shrink tumors. They're often used instead of chemo. ALK inhibitors include:
- Crizotinib.
- Ceritinib.
- Alectinib.
- Brigatinib.
- Lorlatinib.
These medicines are all taken as pills.
Other treatment targets
Scientists have found other gene and protein changes in NSCLC cells that can be the focus of targeted therapy. These cancer cell changes are less common, but if they're found, targeted therapy can be used.
ROS1 gene changes
Changes in the ROS1 gene are most often found in people with the NSCLC subtype called adenocarcinoma. These cancer cells usually don't have ALK or EGFR mutations. Medicines that target abnormal ROS1 include:
- Crizotinib.
- Ceritinib.
- Lorlatinib.
- Entrectinib.
All of these are taken as pills.
BRAF gene changes
Changes in the BRAF gene allow cancer cells to make an altered BRAF protein that helps them grow and spread.
Dabrafenib and trametinib may be used together to treat NSCLCs with a certain kind of BRAF gene mutation. These medicines are taken as pills.
RET fusion gene changes
Abnormal RET proteins are made when the RET fusion is changed. This leads to out-of-control cancer cells growth.
RET inhibitors include:
- Selpercatinib.
- Pralsetinib.
- Cabozantinib.
- Vandetanib.
They attack the RET protein to slow cancer cell growth. They're taken as pills.
MET gene changes
MET gene changes cause cancer cells to make abnormal MET proteins that help them grow and spread.
Capmatinib and tepotinib are MET inhibitors. They attack the MET protein. They're taken as pills.
NTRK fusion gene changes
Changes in NTRK fusion can cause cancer cell growth.
Larotrectinib and entrectinib target and damage the proteins made by the NTRK genes. These medicines are taken as pills.
HER2 gene changes
Human epidermal growth factor receptor 2 can help some cancers grow.
The medicine trastuzumab deruxtecan may be used to target HER2 mutations. It is given by I.V. infusion.